Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. \n\n\n\n\n\n\n\nThe clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. \n\n\n\nThe Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. \n\n\n\nAtriva Therapeutics was founded in 2015 in Germany by a team of scientists in viral research and industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany.\n\n\n\nWe spoke with founder and CEO, Rainer Lichtenberger at BIO-Europe, in Leipzig, Germany. \n\n\n\nLichtenberger is set to retire in 2023, and his successor has been announced as Christian Pangratz.